FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
An advisory committee recommends use of the first psoriasis therapy targeting IL-17A.
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 7-0 to recommend approval of Novartis’ AIN457 (secukinumab) for the treatment of plaque psoriasis for patients who are candidates for systemic therapy or phototherapy. The panel determined the drug was highly efficacious and the 300 mg dose was determined to provide the greatest benefit to patients. When compared with Enbrel (etanercept) in a head-to-head trial last year, secukinumab demonstrated significantly superior efficacy over Enbrel in patients with moderate-to-severe plaque psoriasis.
Unlike many of the tumor necrosis factor (TNF) inhibitors used to treat psoriasis, secukinumab employs a unique first-in-class mechanism of action. The drug, a human IgG1 mAb, targets the function of proinflammatory cytokine IL-17A, a messenger protein typically found in high concentrations in psoriasis skin plaques. IL-17A recruits monocytes and neutrophils to the site of inflammation, and psoriasis patients’ skin is in a constant state of inflammation as a result of this IL-17A activity. Secukinumab works by neutralizing the function of this interleukin.
Assuming secukinumab goes on to win FDA approval, it may have a significant impact on clinical decisions and payer policies, as Enbrel is currently considered the standard of care to treat psoriasis and is the most commonly used drug among TNF inhibitors, according to a study by the Journal of Managed Care Pharmacy.
Novartis filed a biologics license application for secukinumab in October 2013, and the anticipated action date for the drug is in early 2015. Although FDA is not obligated to approve the drug based on the panel’s recommendations, the agency typically approves medications based on panel sanctions.
Sources:
Novartis
http://www.novartis.com/newsroom/media-releases/en/2014/1864296.shtml
http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
